^
Association details:
| Biomarker: | KMT2D mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | decitabine (DNMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia
Published date:
01/22/2021
Excerpt:
KMT2D-mutated cells were more sensitive to decitabine (IC50, Mean ± SEM, 22.2 ± 3.9 vs. 73.6 ± 25.4 μM; p = 0.029; Figure S4C), reduced sensitivity to ibrutinib (IC50 5.3 ± 0.9 vs. 2.9 ± 0.9 μM; p = 0.095) and similar sensitivity to chidamide (IC50 0.6 ± 0.11 vs. 6.9 ± 6.1 μM; p = 0.218) compared with KMT2D wild-type cells. Ibrutinib and decitabine were synergistic (Fig. 2C; p < 0.05) suggesting decitabine increases ibrutinib sensitivity in KMT2D-mutated CLL cells.
DOI:
10.1038/s41375-021-01124-5
